



# 2018 APASL Single Topic Conference on Hepatitis B Virus Taipei

## HBV

APASL STC 2018

## Towards Hepatitis B Elimination - Following Hepatitis C Cure

June 22-24 | Taipei International Convention Center  
Taipei, Taiwan



## Masashi Mizokami



### CURRENT POSITIONS

Director, Genome Medical Sciences Project,  
National Center for Global Health and Medicine, Japan.

### EDUCATIONAL AND CAREER EXPERIENCES

Research area Molecular evolutionary analysis of host and pathogen genome and their clinical application

#### Professional Experience

2016- Present Director, Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan.

2008-2016 Director General, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.

2000-2008 Director and Professor, Department of Clinical and Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

1978-1981 Gastroenterologist, Department of Gastroenterology, Chukyo Hospital, Nagoya, Japan.

1970-1976 Nagoya City University Medical School, Nagoya, Japan.

### PUBLICATION/ AWARDS AND HONORS/ OWNED PATENTS

1. Sugiyama M, Tanaka Y, **Mizokami M**, *et al*. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. **Gastroenterology**. 2009 136:652-62.
2. Tanaka Y, Nishida N, **Mizokami M**, *et al*. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. **Nat Genet**. 2009 41:1105-9.
3. Kuno A, **Mizokami M**, Narimatsu H, *et al*. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. **Sci Rep**. 2013 3:1065.
4. **Mizokami M**, Yokosuka O, Omata M, *et al*. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomized, phase 3 trial. **Lancet Infect Dis**. 2015 15:645-53.
5. Nishida N, Tokunaga K, **Mizokami M**, *et al*. Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis. **Sci Rep**. 2016 6:24767.
6. Kawashima M, **Mizokami M**, Nakamura M. Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. **Hum Mol**



# 2018 APASL Single Topic Conference on Hepatitis B Virus Taipei

## HBV

APASL STC 2018

## Towards Hepatitis B Elimination - Following Hepatitis C Cure

June 22-24

Taipei International Convention Center  
Taipei, Taiwan



**Genet.** 2017 26:650-659.

7. Liu J, Mizokami M, Yang HI, *et al.* Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. **Sci Rep.** 2017 Oct 30;7:14352.
8. Lee MH, Mizokami M, Chen CJ, *et al.* Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study. **Hepatology.** 2017 In press.
9. Murata K, Asano M, Mizokami M, *et al.* Induction of IFN- $\lambda$ 3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. **Gut.** 2018 Feb;67:362-371.
10. Nishida N, Sugiyama M, Mizokami M. Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. **Hepatology.** 2018 In press.